Literature DB >> 8608259

Peripheral blood CD34+ cells differ from bone marrow CD34+ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor.

R E Donahue1, M R Kirby, M E Metzger, B A Agricola, S E Sellers, H M Cullis.   

Abstract

Granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) have been shown to stimulate the circulation of hematopoietic progenitor cells in both mice and nonhuman primates. We evaluated the immunophenotype and cell cycle status of CD34+ cells isolated from the bone marrow (BM) and leukapheresis product of cytokine-mobilized nonhuman primates. CD34+ cells were isolated from rhesus macaques that had received no cytokine therapy, 100 micrograms/kg/d G-CSF, 200 micrograms/kg/d SCF, or a combination of both 100 micrograms/kg/d G-CSF and 200 micrograms/kg/d SCF as a subcutaneous injection for 5 days. BM was aspirated before (day 0) and on the last day (day 5) of cytokine administration. On days 4 and 5, peripheral blood (PB) mononuclear cells were collected using a novel method of leukapheresis. Threefold more PB mononuclear cells were collected from animals receiving G-CSF alone or G-CSF and SCF than from animals that had received either SCF alone or no cytokine therapy. CD34+ cells were positively selected using an immunoadsorptive system from the BM, PB, and/or leukapheresis product. Threefold and 10-fold more CD34+ cells were isolated from the leukapheresis product of animals receiving G-CSF or G-CSF and SCF, respectively, than from animals receiving no cytokine therapy or SCF alone. The isolated CD34+ cells were immunophenotyped using CD34-allophycocyanin, CD38-fluorescein isothiocyanate, and Thy-1-phycoerythrin. These cells were later stained with 4', 6-diamidino-2-phenylindole for simultaneous DNA analysis and immunophenotyping. BM-derived CD34+ cells did not differ significantly in cell cycle status and Thy-1 or CD38 phenotype before or after G-CSF and/or SCF administration. Similarly, CD34+ cells isolated from the leukapheresis product did not differ significantly in immunophenotype or cell cycle status before or after G-CSF and/or SCF administration. However, there were consistent differences in both immunophenotype and cell cycle status between BM- and PB-derived CD34+ cells. CD34+ cells isolated from the PB consistently had a smaller percentage of cells in the S+G2/M phase of the cell cycle and had a higher percentage of cells expressing Thy-1 than did CD34+ cells isolated from the BM. A greater proportion of PB-derived CD34+ cells were in the S+G2/M phase of the cell cycle after culture in media supplemented with interleukin-6 and SCF, However, culturing decreased the proportion of CD34+ cells expressing Thy-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608259

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  Significant mobilization of both conventional and regulatory T cells with AMD3100.

Authors:  Leslie S Kean; Sharon Sen; Olusegun Onabajo; Karnail Singh; Jennifer Robertson; Linda Stempora; Aylin C Bonifacino; Mark E Metzger; Daniel E L Promislow; Joseph J Mattapallil; Robert E Donahue
Journal:  Blood       Date:  2011-10-11       Impact factor: 22.113

2.  In vivo selection of CD4(+) T cells transduced with a gamma-retroviral vector expressing a single-chain intrabody targeting HIV-1 tat.

Authors:  Stephen E Braun; Ran Taube; Quan Zhu; Fay Eng Wong; Akikazu Murakami; Erick Kamau; Markryan Dwyer; Gang Qiu; Janet Daigle; Angela Carville; R Paul Johnson; Wayne A Marasco
Journal:  Hum Gene Ther       Date:  2012-09       Impact factor: 5.695

3.  AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.

Authors:  André Larochelle; Allen Krouse; Mark Metzger; Donald Orlic; Robert E Donahue; Simon Fricker; Gary Bridger; Cynthia E Dunbar; Peiman Hematti
Journal:  Blood       Date:  2006-01-26       Impact factor: 22.113

4.  Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in nonhuman primates.

Authors:  Jagdeep S Walia; Anton Neschadim; Orlay Lopez-Perez; Abdulfatah Alayoubi; Xin Fan; Stéphane Carpentier; Melissa Madden; Chyan-Jang Lee; Fred Cheung; David A Jaffray; Thierry Levade; J Andrea McCart; Jeffrey A Medin
Journal:  Hum Gene Ther       Date:  2011-03-25       Impact factor: 5.695

5.  Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.

Authors:  Robert E Donahue; Ping Jin; Aylin C Bonifacino; Mark E Metzger; Jiaqiang Ren; Ena Wang; David F Stroncek
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

6.  Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells.

Authors:  D S An; R P Wersto; B A Agricola; M E Metzger; S Lu; R G Amado; I S Chen; R E Donahue
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

7.  Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor.

Authors:  C E Dunbar; N E Seidel; S Doren; S Sellers; A P Cline; M E Metzger; B A Agricola; R E Donahue; D M Bodine
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

8.  MASL1 induces erythroid differentiation in human erythropoietin-dependent CD34+ cells through the Raf/MEK/ERK pathway.

Authors:  Chutima Kumkhaek; Wulin Aerbajinai; Wenli Liu; Jianqiong Zhu; Naoya Uchida; Roger Kurlander; Matthew M Hsieh; John F Tisdale; Griffin P Rodgers
Journal:  Blood       Date:  2013-01-17       Impact factor: 22.113

9.  Feline leukemia virus integrase and capsid packaging functions do not change the insertion profile of standard Moloney retroviral vectors.

Authors:  J-Y Métais; S Topp; R T Doty; B Borate; A-D Nguyen; T G Wolfsberg; J L Abkowitz; C E Dunbar
Journal:  Gene Ther       Date:  2010-03-18       Impact factor: 5.250

10.  Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells.

Authors:  Naoya Uchida; Kareem N Washington; Jun Hayakawa; Matthew M Hsieh; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Robert E Donahue; John F Tisdale
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.